Effects of Rosiglitazone on Vascular Protection
Author Information
Author(s): Ren Liqun, Liu Naifeng, Zhi Hong, Li Yingjuan, Li Yanzhi, Tang Rining, Sheng Zulong
Primary Institution: Zhongda Hospital of Southeast University, Nanjing, China
Hypothesis
The study aimed to investigate the effects of the renin-angiotensin system in vascular protection mediated by PPARγ agonists.
Conclusion
Rosiglitazone suppressed VSMC proliferation and early atherosclerotic formation, mediated by reducing local ANG II concentration and modulating angiotensin receptor expression.
Supporting Evidence
- Rosiglitazone significantly reduced lipid deposition and VSMC proliferation in aortic tissues.
- VSMC proliferation induced by ANG II was markedly inhibited by rosiglitazone.
- Rosiglitazone down-regulated AT1R and up-regulated AT2R expression in aortic tissues.
Takeaway
This study found that a drug called rosiglitazone can help protect blood vessels by reducing harmful substances and changing how certain receptors work.
Methodology
Rats were divided into groups and treated with different diets and rosiglitazone, followed by assessments of vascular changes and receptor expression.
Limitations
The study had a small sample size, which may limit the generalizability of the findings.
Participant Demographics
Male Wistar-Kyoto rats, weighing 150-190 g.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website